A process is part of the product
For living-cell products, collection, expansion, storage and administration can affect performance. Developers must control identity, purity, potency and contamination risk while showing that batches remain consistent.
Clinical development
Early studies usually emphasise safety, feasibility and dose. Later controlled studies must show that benefits are meaningful and durable in the intended population. A cosmetically visible outcome also needs standardised photography, hair counts or other defensible assessment methods.
Commercial availability is jurisdiction-specific
A treatment may be investigated or offered under one country’s framework while remaining unapproved elsewhere. Readers should verify the responsible regulator, study sponsor, protocol and informed-consent process rather than relying on labels such as stem-cell treatment or regenerative therapy.